Imatinab mesylate treatment in Chronic Myeloid Leukemia (CML)- understanding the fundamental pharmacokinetic and pharmacogenetic mechanisms for variation in response
Although lmatinib mesylate (IM) is the gold standard drug for Chronic Myeloid Leukemia (CML) treatment, resistance to IM emerges in a significant number of patients. Resistance could be due to several factors. Pharmacokinetic variability as a result of genetic polymorphisms in IM metabolizing gen...
| Main Author: | |
|---|---|
| Format: | Monograph |
| Language: | English |
| Published: |
Pusat Pengajian Sains Perubatan, Universiti Sains Malaysia
2016
|
| Subjects: | |
| Online Access: | http://eprints.usm.my/58151/1/PROF%20DR%20RAVINDRAN%20ANKATHIL-Eprints.pdf |